TICKERNERD
Menu
VCELVCELHealthcare · Biotechnology

VCEL Stock Forecast: Vericel Corp. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$40
−0.22% on the day

The 8 Wall Street analysts covering Vericel Corp. hold a median 12-month price target of $59 — +46.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 13 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.1B
Ticker Nerd rank
94 / 100
Median analyst target
$59
Analysts covering
8
Revenue$77.5M+22.5% y/y
Operating income$434K
Net income$2.2M
Free cash flow$14.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
+1.5%
YTD
+11.7%
1Y
+16.1%
From 52W high
−16.8%
From 52W low
+37.0%
$29
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VCEL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vericel Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
95
Growth
81
Revisions
77
Accruals
74
Issuance
73
Momentum
70
Volatility
62
Value
57
Size
35

Quality (95): The business earns solid, repeatable profits on what it owns.

Value (57): The shares cost a lot relative to the profits and assets behind them.

Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VCEL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VCEL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26VCELHigh $72Median $59Low $55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $55Median $59High $72

The green dot is the last close — the median target sits +46.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
31 July 2026HC Wainwright & Co.MaintainsBuy$70 → $72
31 July 2026TD CowenMaintainsBuy$55 → $58
31 July 2026Truist SecuritiesReiteratesBuy$54 → $58
28 July 2026HC Wainwright & Co.ReiteratesBuy$70
16 July 2026Truist SecuritiesMaintainsBuy—
16 July 2026Truist SecuritiesMaintainsBuy$42 → $54
8 May 2026HC Wainwright & Co.MaintainsBuy—
15 Apr 2026Truist SecuritiesMaintainsBuy—
27 Feb 2026HC Wainwright & Co.MaintainsBuy—
18 Dec 2025Truist SecuritiesMaintainsBuy—
10 Nov 2025Truist SecuritiesReiteratesBuy—
15 Oct 2025Truist SecuritiesMaintainsBuy—
17 Sept 2025BTIGDowngradeNeutral—
1 Aug 2025Canaccord GenuityMaintainsBuy—
16 June 2025Stephens & Co.ReiteratesOverweight—
22 May 2025Stephens & Co.ReiteratesOverweight—
11 Apr 2025Truist SecuritiesMaintainsBuy—
3 Mar 2025Truist SecuritiesReiteratesBuy—
28 Feb 2025HC Wainwright & Co.ReiteratesBuy—
3 Feb 2025Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VCEL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VCEL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Vericel Corp. returned +16.1% against +18.7% for the S&P 500, dividends included.

VCEL vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26VCELS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VCEL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+14.2%
Analysts raising
1
Analysts cutting
0
Fundamentals

Vericel Corp. (VCEL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
85.7×

Cheaper than 8% of US stocks

Price / sales
6.7×

Cheaper than 19% of US stocks

Price / book
5.6×

Cheaper than 17% of US stocks

EV / EBITDA
64.0×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
22.5%

Higher than 71% of US stocks

Earnings growth (YoY)
22.5%

Higher than 60% of US stocks

Gross margin
72.8%

Higher than 85% of US stocks

Operating margin
0.6%

Higher than 46% of US stocks

Net margin
7.9%

Higher than 66% of US stocks

Returns & dividend
Return on equity
7.2%

Higher than 57% of US stocks

Return on assets
2.4%

Higher than 61% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vericel Corp. (VCEL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vericel Corp. has a market value of $2.1B and an enterprise value of $2.0B.

  • Revenue in the twelve months to 30 June 2026: $306.3M. The latest quarter grew 22.5% year on year.

  • Net income over the same four quarters: $24.2M, a 7.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.47.

  • Free cash flow in the twelve months to 30 June 2026: $61.7M, after $8.0M of capital spending.

  • Shares outstanding: 51.2M.

  • Trailing P/E: 85.7×; forward P/E: 47.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Vericel Corp. employs 398 people — $770K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

VCEL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VCELVericel Corp.$2.1B
94
IMNMImmunome, Inc.$2.1B
31
PHVSPharvaris NV$2.1B
39
VRDNViridian Therapeutics, Inc.$2.0B
48
RXRXRecursion Pharmaceuticals, Inc.$2.0B
43
NVAXNovavax, Inc.$2.1B
61
FTREFortrea Holdings, Inc.$2.0B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vericel Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VCEL news & analysis

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Vericel Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its remarks was published on Seeking Alpha. The coverage focuses on the company's participation at the conference.

Why it matters — A VCEL watcher would care because the transcript offers direct insight into the company's recent commentary and updates shared with investors at the conference.

Vericel: MACI And Regenerative Knee Cartilage

Seeking Alpha · 15 Sept 2026positive

Seeking Alpha highlights Vericel's MACI therapy, noting its established commercial base and arthroscopic delivery as growth facilitators. The article also points to the company's new BARDA contract supporting its Burn Care business, plus potential UK launch and ankle indication developments.

Why it matters — The piece underscores multiple growth catalysts for VCEL, including expanded capacity at Burlington, a new BARDA contract, and potential new market and indication launches.

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

GlobeNewsWire · 8 Sept 2026neutral

Vericel Corporation announced it will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026. The company, a leader in advanced therapies for sports medicine and severe burn care, made the announcement on September 8, 2026.

Why it matters — A presentation at a major healthcare conference gives Vericel a platform to update investors and industry participants on its business, which VCEL watchers may follow for insights into the company's progress.

Vericel Q2 Earnings Call Highlights

MarketBeat · 30 July 2026positive

Vericel reported record second-quarter revenue and raised its full-year outlook, driven by growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.

Why it matters — The strong quarterly performance and upward revision to the full-year forecast signal sustained momentum in Vericel's core product lines and improving financial health.

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

Seeking Alpha · 30 July 2026neutral

Vericel Corporation held its Q2 2026 earnings conference call, and the transcript of that call was published by Seeking Alpha.

Why it matters — Investors tracking Vericel can review management's discussion of second-quarter performance and outlook as detailed in the earnings call transcript.

FAQ

Frequently asked questions about VCEL stock

What is the VCEL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Vericel Corp. have a median 12-month price target of $59, with estimates ranging from $55 to $72. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VCEL stock a buy right now?

Of the 8 analysts covering Vericel Corp., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vericel Corp. 94 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VCEL?

As at 13 Oct 2026, Vericel Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (95 of 100).

Will VCEL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +46.7% from the last close, and Ticker Nerd's factor model ranks Vericel Corp. 94 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VCEL stock forecast for 2030?

No analyst covering Vericel Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $55 to $72 over the next 12 months.

How has VCEL stock performed over the past year?

Vericel Corp. returned +16.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vericel Corp. do?

Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for sports medicine and severe burn care. Vericel develops, manufactures, and markets products that support the repair of damaged tissue and the restoration of function in patients with serious injuries.

What is the latest news on VCEL?

The most recent item we track (Seeking Alpha, 16 Sept 2026): "Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Vericel Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its remarks was published on Seeking Alpha. The coverage focuses on the company's participation at the conference.

Company

About Vericel Corp.

Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for sports medicine and severe burn care. Vericel develops, manufactures, and markets products that support the repair of damaged tissue and the restoration of function in patients with serious injuries. Its commercial portfolio includes MACI, a cell therapy used in knee cartilage repair; Epicel, a skin replacement product for severe burns; and NexoBrid, an enzymatic biologic used for eschar removal in burn care. The company serves hospitals, surgeons, and specialized care teams across the United States, with its products positioned within regenerative medicine and acute wound care. Vericel’s business centers on translating cell-based science into practical treatments for complex orthopedic and burn-related conditions.

CEO Mr. Dominick C. Colangelo Esq. · 398 employees · United States · https://www.vcel.com